Hospital de Clínicas de Porto Alegre, Infectious Diseases Service, Porto Alegre, RS, Brazil.
Hospital de Clínicas de Porto Alegre, Infectious Diseases Service, Porto Alegre, RS, Brazil; Universidade Federal de Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil.
Braz J Infect Dis. 2020 Sep-Oct;24(5):455-457. doi: 10.1016/j.bjid.2020.07.009. Epub 2020 Aug 26.
COVID-19 pandemic has been a problem worldwide. It is important to identify people at risk of progressing to severe complications and to investigate if some existing antivirals could have any action against SARS-CoV-2. In this context, HIV-infected individuals and antiretroviral drugs might be included, respectively. Herein we present the case of a 63-year-old HIV-infected woman with undetectable viral load, on dolutegravir, tenofovir and lamivudine, who was hospitalized due to COVID-19 pneumonia. In spite of having some clinical markers of severity on admission, the patient improved and was discharged after a week. To our knowledge, this is the first report of severe SARS-CoV-2 infection in an HIV-infected individual in Brazil.
新型冠状病毒肺炎(COVID-19)大流行是一个全球性问题。重要的是要识别出有进展为严重并发症风险的人群,并研究是否有一些现有的抗病毒药物对 SARS-CoV-2 有作用。在这方面,可以分别考虑感染艾滋病毒的个体和抗逆转录病毒药物。在此,我们介绍了一位 63 岁的 HIV 感染者的病例,该患者的病毒载量无法检测,服用多替拉韦、替诺福韦和拉米夫定,因 COVID-19 肺炎住院。尽管入院时有一些严重的临床标志物,但患者在一周后得到改善并出院。据我们所知,这是巴西首例 HIV 感染者严重 SARS-CoV-2 感染的报告。